Dihomo gamma linolenic acid - first generation

Drug Profile

Dihomo gamma linolenic acid - first generation

Alternative Names: 8,11,14-eicosatrienoic-acid; all-cis-8,11,14-eicosatrienoic-acid; Bishomo-gamma-linolenic acid; DGLA; DHLA; Dihomogammalinolenic-acid; DS 107E; DS-107G; DS-107J; DS107; Gamma-homolinolenic-acid; Homo-gamma-linolenic-acid; RO-12-1989

Latest Information Update: 17 Jan 2017

Price : $50

At a glance

  • Originator Dignity Sciences
  • Developer DS Biopharma
  • Class Eicosanoids; Omega-6 fatty acids; Skin disorder therapies; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acne vulgaris; Atopic dermatitis
  • Preclinical Radiation-induced skin damage; Wounds

Most Recent Events

  • 16 Jan 2017 DS Biopharma initiates enrolment in a phase IIb trial in Atopic dermatitis in USA (PO, Capsule)
  • 06 Jan 2017 Phase-II clinical trials in Atopic dermatitis in USA (Topical, Cream)
  • 19 Oct 2016 DS Biopharma plans a phase II trial for Atopic dermatitis in USA (Topical, Cream) (NCT02925793)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top